BioSpace News Archive

QurAlis Corporation today announced the presentation of preclinical findings from its STATHMIN-2 (STMN2) program,

Eyenovia, Inc. (NASDAQ: EYEN), today announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from Latanoprost+Benzalkonium Chloride (BAK) treatment administered via Optejet versus Latanoprost+BAK administered via standard eye drops.

Xtant Medical Holdings, Inc. announced that Sean Browne, President and Chief Executive Officer, will present at the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022, at 2:00 p.m. Central Time in Chicago.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET).

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of March 2022, which is payable on April 15, 2022 to shareholders of record at the close of business on March 31, 2022.

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will host a key opinion leader (KOL) webinar on the use of Deep TMS™ Therapy for treating anxious depression on Tuesday, March 22, 2022, at 10:30 am Eastern Time.

Shoreline Biosciences, Inc., a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells utilizing its proprietary iPSC-derived natural killer cell and macrophage platforms, announced the appointment of Robert Hollingsworth, Ph.D., as its Chief Scientific Officer.

AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.

Ascentage Pharma announced that it has dosed the first patient in the pivotal Phase II study of the company’s novel Bcl-2 selective inhibitor, lisaftoclax, for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in China.